Molecular Magnetic Resonance Imaging with Contrast Agents for Assessment of Inflammatory Bowel Disease: A Systematic Review

Yifan Luo, Chen Gao, Wujie Chen, Kefeng Zhou and Maosheng Xu

1The First Clinical Medical College of Zhejiang Chinese Medical University, Hangzhou 310053, China
2Department of Radiology, The First Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou 310006, China
3Department of Radiology, Tongde Hospital of Zhejiang Province, Hangzhou 310012, China

Correspondence should be addressed to Maosheng Xu; xums166@zcmu.edu.cn

Received 8 March 2020; Revised 20 April 2020; Accepted 25 April 2020; Published 6 May 2020

Academic Editor: Guillermina Ferro-Flores

Copyright © 2020 Yifan Luo et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Background and Aims. Magnetic resonance imaging (MRI) has taken an important role in the diagnosis of inflammatory bowel diseases (IBD). In the wake of current advances in nanotechnology, the drug delivery industry has seen a surge of nanoparticles advertising high specificity in target imaging. Given the rapid development of the field, this review has assembled related articles to explore whether molecular contrast agents can improve the diagnostic capability on gastrointestinal imaging, especially for IBD.

Methods. Relevant articles published between 1998 and 2018 from a literature search of PubMed and EMBASE were reviewed. Data extraction was performed on the studies’ characteristics, experimental animals, modelling methods, nanoparticles type, magnetic resonance methods, and means of quantitative analysis.

Results. A total of 8 studies were identified wherein the subjects were animals, and all studies employed MR equipment. One group utilized a perfluorocarbon solution and the other 7 groups used either magnetic nanoparticles or gadolinium- (Gd-) related nanoparticles for molecular contrast. With ultrasmall superparamagnetic iron oxide (USPIO) particles and Gd-related nanoparticles, signal enhancements were found in the mucosa or with focal lesion of IBD-related model in T1-weighted images (T1WI), whereas superparamagnetic iron oxide (SPIO) particles showed a signal decrease in the intestinal wall of the model in T1WI or T2-weighted images. The signal-to-noise ratio (SNR) was employed to analyze bowel intensity in 3 studies. And the percentage of normalized enhancement was used in 1 study for assessing the severity of inflammation.

Conclusion. Molecular MRI with contrast agents can improve the early diagnosis of IBD and quantify the severity of inflammation in experimental studies.

1. Introduction

Inflammatory bowel disease (IBD), including Crohn’s disease (CD) and ulcerative colitis (UC), is a chronic, relapsing illness. The worldwide incidence of IBD has increased over the years, especially in western countries and newly industrialized countries [1, 2].

As a method for noninvasive examination, radiology takes an important role in the diagnoses of IBD by evaluating lesions in the intestinal wall. Compared with computed tomography (CT), magnetic resonance imaging (MRI) obtains high-quality images without harmful ionizing radiation, making it a more suitable modality for patients who require long-term follow-up, teenagers, and young adults. With a higher spatial resolution as well as various sequences, MRI is adapted to help diagnose IBD early and assess disease activity [3]. However, contrast-enhanced MRI sequences are often required for such diagnostic accuracy.

With the development of nanotechnology, new molecular probes have been developed for targeted imaging to evaluate lesions and surrounding tissues. The majority of the molecular contrast agents play a passive targeting role by being susceptible to macrophage clearance. Therefore, several studies rely on nanoparticles to monitor inflammation in the cardiovascular and nervous systems related to macrophage dysplasia [4–6]. On the other hand, active targeting probes can target track lesions via intracellular trapping. These modalities are mainly used in the evaluation of carcinomas and cardiovascular diseases [6]. It is worth noting that macrophage dysplasia also exists in intestinal
inflammation and mucosal barrier damage in inflammatory regions increases permeability to some substances, providing a basis for the application of molecular imaging in the intestinal system [7, 8].

In this review, we assembled animal studies regarding magnetic resonance (MR) intestinal imaging using molecular contrast agents in the last twenty years. This review seeks to explore the advantages and characteristics of molecular imaging for the early diagnosis and quantitative assessment of IBD. We also assess the feasibility of molecular imaging for future clinical translation.

2. Materials and Methods

A systematic search of published studies in PubMed and EMBASE from 1998 to 2018 was conducted. Each database was searched for “magnetic resonance imaging” or “magnetic resonance” and “nanoparticle” or “nanoparticles” or “nanocrystalline material” or “nanocrystal” or “nanocrystals” and “gastrointestinal Tract” or “gastrointestinal tracts” or “GI tract” or “GI tracts” or “digestive tract” or “digestive system”. No language restrictions were applied, and the references from selected articles were also scanned for additional relevant studies. The protocol for this review was registered on PROSPERO (http://www.crd.york.ac.uk/PROSPERO; CRD42019127236).

In the last two decades, molecular imaging was widely used to assess inflammation in the cardiovascular and nervous systems. However, literature regarding its use in intestinal imaging is scarce. Therefore, our group examined relevant literature without adding intestinal keywords to avoid excluding related articles.

Titles and abstracts of potentially relevant studies were examined to determine whether they fulfilled the following inclusion criteria (see Figure 1): (1) studies must apply molecular materials to intestinal imaging and (2) use MR equipment. Articles that explored intestinal imaging ex vivo, in vitro, and in silico models were excluded. After reading the full text, articles which used either a spontaneous intestinal tumor model or only used molecular materials as the neutral contrast agent were also excluded. In the end, all articles either (1) assessed molecular probes designed for IBD diagnosis using healthy animals or (2) assessed molecular imaging for IBD or colitis-associated colorectal cancer models.

Data extraction was performed for animal species, sex, weight, age, the type of molecular contrast agent, administration method, absorption mechanism, MR equipment, MR sequence, and histological confirmation.

3. Results

Our literature search yielded 848 potentially relevant studies which used nanoparticles in MRI studies. There were 840 studies excluded for reasons listed in Figure 1. Characteristics of the 8 included studies were summarized in Tables 1 and 2.

3.1. Subjects. There were 8 studies matched the search criteria in which animal models of mice, rats, and rabbits were employed in articles 5, 2, and 1, respectively. Molecular MR imaging was facilitated in all 8 studies except for one, in which MRI was combined with single-photon emission computed tomography (SPECT/CT) [9]. Positive contrast agent was employed in 3 studies which showed abnormal strengthening in inflammation or colitis-associated dysplasia [10, 13, 14]. Another 2 groups used magnetic nanoparticles (MNPs) that showed signal intensity decreases in inflammatory lesions [9, 11]. Actively targeted nanoparticles were used in 2 studies, which can reach the lower digestive tract through oral administration and improve intestinal imaging [12, 15]. Perfluorocarbon (PFC) was adopted to track macrophages in one study [16].

3.2. Experimental Animals. In the 5 murine studies, C57/B6, C56B6L, nude mice, and A/J mice were used, respectively [9, 11–13, 16]. The majority of studies used mice aged 5 to 8 weeks except for one study which used adult mice. Two studies adopted Lewis rats aged 8 to 12 weeks with an average weight of 220 to 270 g and Sprague Dawley rats with a 190 to 210 g body weight [10, 14]. The final study used a healthy rabbit at 2.7 kg in mass [15]. For modelling methods, three studies used healthy animals [12, 14, 15], two applied dextran sodium sulfate (DSS) to induce colitis in a mice model [9, 11], one used 2,4-dinitrobenzene sulfonic acid (DNBS) for colitis induction [10], and two groups treated mice with azoxymethane and DSS to generate a colitis-associated colorectal cancer model [13, 16].

3.3. Contrast Agents. PFC emulsions were used in 1 study [16] while other studies used nanoparticles. Four employed MNPs [9–12] and the other 3 adopted gadolinium- (Gd-) related nanoparticles [13–15].

3.3.1. MNPs. In the MNP group, studies used ferumoxides (5 x 10⁶ superparamagnetic iron oxide (SPIO) nanoparticle-labeled macrophages per mice) [9], Nanotex (0.5 mg Fe/ml, 100 μL per mice) [11], and casein-coated indocyanine green-loaded iron oxide nanoparticles (CN-ICG-IO) (10 mg Fe/kg) pertaining to SPIOs [12], while 1 study [10] used SHU 555C (5.6 mg Fe/kg) pertaining to USPIOs.

SHU 555C and Nanotex were taken up by the colon reticuloendothelial system (RES) to image inflammatory sites via intravenous administration [10, 11]. Wu et al. labelled macrophages with ferumoxide ex vivo and transfused the labelled cells back to the subject [9]. All studies located inflammatory sites by tracking the migration and distribution of macrophages.

In a separate study, CN-ICG-IO is enclosed by casein and modified with polyethylene glycol (PEG), which can be taken orally [12]. In another study, Nanotex combined with anti-inflammatory agents made it possible to integrate both diagnosis and treatment, creating a theranostic modality [11]. In histological confirmation, MNP groups used Prussian blue staining.
3.3.2. Gd-Related Nanoparticles. Sun et al. [13] treated animals with Gd-loaded solid lipid nanoparticles (SLNs) (40 mg/ml, Gd-diethylenetriaminepentaacetic acid (Gd-DTPA) with a loading rate of ∼30%) by enema. The nanoparticles showed preferential accumulation in lesion areas due to colitis-associated, high-grade intraepithelial neoplasia, which creates higher permeability than healthy tissue. Cheng et al. [14] used Gd-DTPA-loaded chitosan nanoparticles (Gd in chitosan) (14.2 mg/ml, Gd-DTPA with a loading rate of 74.4%), and Perera et al. [15] used PEG-coated, Prussian blue nanoparticles (Gd in PBNPs) (138.9 mg NPs/kg). Both of the aforementioned materials can be endocytosed to enhance colon mucosal uptake while the former is given by rectal administration and the latter is given by oral administration. In histological confirmation, Gd-loaded nanoparticles were combined with fluorescein isothiocyanate (FITC) to verify that material is absorbed by tissue [13].

3.3.3. Perfluorocarbon Solution. Shin et al. [16] treated colitis-associated dysplasia mice with PFC (200 mg/ml, 200 µl per mice) via tail vein iv injection. A $^{19}$F signal to noise was used to track labelled macrophages and assess the lesion area. In their study, inflammation in the descending colon was significantly increased compared to the ascending colon, while colitis-associated dysplasia and adenoma only appeared in descending colon. This finding proved that the occurrence of adenoma was closely related to that of inflammation.

3.4. MR Imaging Protocols. For the 5 murine studies, one group [11] used 7 T MRI equipment, one group [9] used 9.4 T MRI equipment, and one group [16] used 11.7 T MRI equipment while other groups [12, 13] used clinical 3.0 T or 3 T MRI equipment, and some studies [11, 16] mentioned the use of a 16–20 mm surface coil. In rat studies, one study [10] used a 2.4 T MRI and the other [14] used a clinical 3.0 T MRI equipment with a brain crossed coil. In the rabbit study, a clinical 1.5 T MRI was used [15].

For sequence selection, the PFC group [16] adopted a rapid acquisition with refocused echoes (RARE) sequence (repetition time (ms) (TR)/echo time (ms) (TE) = 1200/30 ms for $^1$H images and TR/TE = 1000/14 ms for $^{19}$F images). In the MNP group, ferumoxides [9] used a T1-
Table 1: A summary of molecular MR contrast agents.

<table>
<thead>
<tr>
<th>NPs</th>
<th>Material</th>
<th>Core</th>
<th>Coating</th>
<th>Animal model</th>
<th>Target</th>
<th>Characteristics</th>
</tr>
</thead>
<tbody>
<tr>
<td>MNPs</td>
<td>Ferumoxides [9]</td>
<td>Fe$_3$O$_4$</td>
<td>Dextran</td>
<td>DSS-induced colitis mice model</td>
<td>Macrophage (ex vivo cell labelling)</td>
<td>Adept for cell tracking</td>
</tr>
<tr>
<td></td>
<td>SHU 555C [10]</td>
<td>Iron oxide</td>
<td>Carboxydextran</td>
<td>DNBS-induced colitis Lewis rat model</td>
<td>RES</td>
<td>Positive contrast in MNPs</td>
</tr>
<tr>
<td></td>
<td>CN-ICG-IO [12]</td>
<td>Iron oxide</td>
<td>Casein</td>
<td>Healthy nude mice</td>
<td>Gastrointestinal mucosal</td>
<td>Oral administration</td>
</tr>
<tr>
<td></td>
<td>PEG-coated Gd in PBNPs [15]</td>
<td>Gd in PBNPs</td>
<td>PEG</td>
<td>Healthy rabbit</td>
<td>Gastrointestinal mucosal</td>
<td>Oral administration, PBNP increases absorptivity</td>
</tr>
<tr>
<td></td>
<td>PFC emulsion [16]</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>AOM- and DSS-induced mice model</td>
<td>Macrophage</td>
</tr>
</tbody>
</table>

AOM, azoxymethane; CN-ICG-IO, casein-coated indocyanine green loaded iron oxide nanoparticle; DNBS, 2,4-dinitrobenzene sulfonic acid; DSS, dextran sodium sulfate; DTPA, diethylenetriaminepentaacetic acid; FITC, fluorescein isothiocyanate; Gd, gadolinium; MNPs, magnetic nanoparticles; NPs, nanoparticles; PBNPs, Prussian blue nanoparticles; PEG, polyethylene glycol; PFC, perfluorocarbon; RES, reticuloendothelial system; SLN, solid lipid nanoparticles.

Table 2: The applications of molecular contrast agents MRI in IBD-related model.

<table>
<thead>
<tr>
<th>NPs</th>
<th>Material</th>
<th>Field strength</th>
<th>Sequences</th>
<th>Enhancement$^a$</th>
<th>Administration</th>
<th>Procedures</th>
</tr>
</thead>
<tbody>
<tr>
<td>MNPs</td>
<td>Ferumoxides [9]</td>
<td>9.4 T</td>
<td>T1WI</td>
<td>Intestinal wall T1WI ($)</td>
<td>iv</td>
<td>Long enhancement sustained time, quantitative analysis</td>
</tr>
<tr>
<td></td>
<td>SHU 555C [10]</td>
<td>2.4 T</td>
<td>T1WI, T2WI, T2$^*$</td>
<td>Mucosa T1WI ($) deep colon wall T1WI ($) &amp; T2WI ($)</td>
<td>iv</td>
<td>Quantitative analysis</td>
</tr>
<tr>
<td></td>
<td>Nanotex [11]</td>
<td>7 T</td>
<td>T1WI</td>
<td>Colon wall T1WI ($)</td>
<td>iv</td>
<td>Integration of diagnosis and treatment</td>
</tr>
<tr>
<td></td>
<td>CN-ICG-IO [12]</td>
<td>3 T</td>
<td>T2WI</td>
<td>NA$^b$</td>
<td>po</td>
<td>Oral administration, potential to monitor inflammation and targeted delivery</td>
</tr>
<tr>
<td>Gd-related NPs</td>
<td>Gd-FITC-SLN [13]</td>
<td>3.0 T</td>
<td>T1WI</td>
<td>Focal lesion T1WI ($)</td>
<td>pr</td>
<td>Targeted imaging through intestinal absorption, low Gd deposition, quickly metabolized</td>
</tr>
<tr>
<td></td>
<td>Gd in chitosan nanoparticles [14]</td>
<td>3.0 T</td>
<td>T1W</td>
<td>Mucosa T1WI ($)$^b$</td>
<td>pr</td>
<td>Targeted imaging through intestinal absorption, low Gd deposition</td>
</tr>
<tr>
<td></td>
<td>PEG-coated Gd in PBNPs [15]</td>
<td>1.5 T</td>
<td>T1WI</td>
<td>NA$^b$</td>
<td>po</td>
<td>Potential to monitor inflammation or targeted delivery, low Gd deposition, oral administration</td>
</tr>
<tr>
<td>PFC</td>
<td>PFC emulsion [16]</td>
<td>11.7 T</td>
<td>T1WI</td>
<td>Special$^{19}$F signal in focal lesion</td>
<td>iv</td>
<td>Quantitative analysis; not affected by bowel movements or the existence of air pocket</td>
</tr>
</tbody>
</table>

$^a$ Targeting specific tissues or organs.$^b$ Healthy animals were used in the experiment.$^c$ Signal increased.$^d$ Signal decreased.$^e$ Special 19F signal in focal lesion.
quantitative evaluation [16]. Finally, one group utilized the percentage normalized en-
wascalculated by dividing the signal intensity of the samples (SNR) to analyze the region of interest [10, 13, 16]. wV_he SNR allowed the tracking and assessment of intestinal inflam-
material concentration [12].

demonstrated severe signal distortion through excessive
artifacts, gradient-echo sequences, and T2
T1WI. However, due to inherent artifacts or susceptibility
[9, 11]; it was found that signal intensity decreased in
induced colitis with MNPs via intravenous injection
after contrast enhancement. Two groups treated DSS-
unenhanced T2WI which presented as hypointensities
deep colon wall structures showed hyperintensity on
with colitis after USPIO administration [10]. Meanwhile,
intestinal epithelial cells.

achieved notable increases in signal through endocytosis by
orally showed signal increases as well [15], through the
Gd-DTPA. Nanoparticle-based gadolinium administered
increase in signal intensity along with the control group of
particles [13, 14] administered rectally showed a substantial
Gd-related contrast agents [13, 14] allowed significant en-

3.5. Molecular Imaging and Improved Diagnostics. Gd-related contrast agents [13, 14] allowed significant enhan-
cer in image quality for T1WI. Gd-based nano-
particles [13, 14] administered rectally showed a substantial increase in signal intensity along with the control group of Gd-DTPA. Nanoparticle-based gadolinium administered orally showed signal increases as well [15], through the addition of Prussian blue, and the aforementioned modality achieved notable increases in signal through endocytosis by intestinal epithelial cells.

Mucosal enhancement was observed in T1WI of rats with colitis after USPIO administration [10]. Meanwhile, deeper colon wall structures showed hyperintensity on unenhanced T2WI which presented as hypointensities after contrast enhancement. Two groups treated DSS-
duced colitis with MNPs via intravenous injection
[9, 11]; it was found that signal intensity decreased in T1WI. However, due to inherent artifacts or susceptibility artifacts, gradient-echo sequences, and T2*, these sequences could not be used [9, 10]. An additional study demonstrated severe signal distortion through excessive material concentration [12].
The PFC group employed ParaVision software to combine a pseudocolor 19F signal with 1H imaging [16]. This allowed the tracking and assessment of intestinal inflammation through the distribution of the 19F signal.

Finally, three groups utilized the signal-to-noise ratio (SNR) to analyze the region of interest [10, 13, 16]. The SNR was calculated by dividing the signal intensity of the samples by the standard deviation of the background noise [17]. Finally, one group utilized the percentage normalized enhancement (%NENH) between the intestine and liver for quantitative evaluation [16].

4. Discussion

4.1. Molecular Contrast Agent Selection. MNPs are nano-
particles with iron and iron oxides as the main magnetic
substances which have a higher relaxation degree and stronger effect on local magnetic fields than gadolinium-type
molecular probes [18]. These include superparamagnetic
type
iron oxide (SPIO) and ultrasmall superparamagnetic iron
oxide (USPIO) particles. SPIOs such as ferucarbotran (SHU 555 A) are often more than 20 nm in diameter, with a core of Fe3O4 or Fe2O3 and modification with carbon, oxygen, or

According to different chemical compositions, particle
sizes, and surface properties, MNPs can be divided into T1W agents and T2W agents [20]. USPIO classifies as a T2W agent while USPIO has a greater T1 effect. The characteristics of positive enhancement make USPIO more suitable for di-
agnostic use. Like other organs and tissues, the MNP system
has the ability to enter the colonic RES through circulation
[9, 10]. Yet, signal distortion can negatively impact diagnosis if the local concentration is too high [10, 12].

Compared with the MNPs, gadolinium-like molecular
probes do not have magnetic susceptibility artifacts. SLNs
are a type of colloidal particle made from protein, den-
 drimer, or liposomes. Their sizes range between 50 and
1000 nm and they are biocompatible, biodegradable, and
easily absorbed by the digestive tract [21].

Leukocytes, such as macrophages, are commonly
recruited in inflammatory reactions. Because of this, their
migration can be traced using a molecular contrast agent
(Figure 2). While most contrast agents require intrave-
nous administration, SLNs are mainly absorbed via the
intestinal tract (Figure 3). When given orally, absorption
by the stomach accounts for less than 5% of total uptake
[29]. It has been reported that about 50% of SLNs can be
absorbed directly through intestinal mucosa or inter-
cellularly, and the absorption correlates linearly within a
certain concentration [21]. Specifically, M-cells overlying
the lymphoid follicles and Peyer’s patches may be the
main ways SLNs enter the gut mucosa [25]. About 70% of
absorbed SLNs were taken in circulation through the
lymphatic system [21]. The remainder was transported
directly through blood circulation, possibly via capillaries
or intestinal epithelial cells by the paracellular route
[26–28].

However, different conditions exist in pathological sit-
uations. Wu et al. [30] revealed that in DMH-treated mice,
SLNs were primarily absorbed via carcinogenic colorectal
mucosa and directly into the submucosal capillary network.

Other studies have shown that the cell junction protein,
zonula occludens 1, was imparted in the inflammatory state
[8]. This led to expansions in the cell junctions and increased
permeability, resulting in increased uptake in the carcino-
ogenic regions. Using lymphatic transport, SLNs were able to
avoid first past metabolism in the liver and increase ab-
sorption and efficacy.

Some controversy exists regarding the absorption of
SLNs through the gut. One study demonstrated that de-
tection of the SLN complex in intestinal epithelial cells was
difficult when using a water-quenching, near-infrared (NIR)
fluorescent probe [31]. Another experiment showed that
SLNswithloadeddrugscanpassthroughepithelialcellsinaintestinalcapillaries,whilelipidsremainmostlyincells[32].ThecharacteristicsofSLNsmaybeaffectedbydifferent
surface modifications as well as different manufacturing
processes. Yet, multiple animal experiments have confirmed
thatSLNs can greatly improve the uptake and transport of
the drugs loaded by intestinal epithelial cells [25, 33, 34].

For nanoparticle surface modifications, Gd in PBNPs
utilizedPEGtoimprovethesustainedreleaseandextendthe
therapeutic window [15]. Both animal experiments [35] and
clinical studies [36] found that PEG-modified drugs were
moreinclinedtodepositatthelesion,whichmayberelated
totheadnornalstateofintestinalmucosaduringinflam-
mation. Additionally, it was found that Prussian blue can
also be used in conjunction to enhance the drugs’ pen-
etration [20].

The use of $^{19}$Fto trace cell migration in MRI imaging is
based on the sensitivity of the $^{19}$F nucleus relative to $^1$H.
Compared to metal ion contrast agents, PFC is nontoxic and
has been applied for cell tracking in aclinical setting [37].

For the use of contrast agents, Wu et al. [9] reinjected
labelledmacrophagesvialtailveinintravenously.Threestudies [10, 11, 16] adopted intravenous injection, two
studies [13, 14] used rectal administration, and the other two
studies [12, 15] used oral ingestion. Aiming to improve
intestinal absorption, the nonintravenous groups used SLNs,
chitosan, casein, or PEG to wrap the core material. Except
forchitosan-basedNPs, allothermaterialsallowfororal
administration. Compared to intravenous administration,
theoralrouteisfarlessinvasivewithfewer side effects and
improved compliance.

4.2. Imaging Optimization. For the development of the
animal study, three key modalities were used. DSS induces
inflammation in intestinal indiscriminately, while 2, 4, 6-
trinitrobenzene sulfoic acid (TNBS) and DNBS can induce
particolorectal inflammation through topical adminis-
tration. Therefore, TNBS and DNBS may provide an op-
portunity to observe the difference between normal tissue
and inflamed intestinal tissue in the same segment.

The majority of studies used mice aged 5–8 weeks, which
provided a better model for bowel inflammation. Acute models
are suitable for analyzing short-term barrier changes and innate
immune effects and flares. On the other hand, chronic models
are able to illustrate the role of adaptive immunity, neoplasia,
and tissue fibrosis [38]. While a rat or rabbit model has advan-
tages for imaging due totheir size, murine models can also
achieve the same resolution if an appropriate coil is used to display the intestinal wall contour [13, 30].

Intestinal tract peristalsis and pneumatosis can induce nonspecific hypointensities and complicate the use of SPIO for the diagnosis of bowel diseases. To combat this issue, Wu et al. [9] treated mice with MnCl₂ to delineate the intestinal contour, which allowed SPIO to distinguish the bowel wall from the intestinal cavity. Currently, oral administration of MnCl₂ is approved by the Food and Drug Administration [39].

With gadolinium-like molecular probes, it has been reported that fluid-attenuated inversion recovery (FLAIR) is more sensitive to low-concentration gadolinium imaging [40]. In light of this, one study used FLAIR to collect high-resolution images in mice on a 1.5 T clinical scanner [30].

4.3. Future Expectations. Nanomaterials allow an unparalleled versatility in their ability to be loaded with therapeutic agents, genetic material, and various other compounds for treatment. For instance, Ohno et al. [41] treated murine colitis with nanoparticles loaded with curcumin. Zhang et al. [42] synthesized a redox-responsive β-cyclodextrin (OxbCD) and prepared Tempol- (TpL-) loaded OxbCD particles (TpL/OxbCD NPs) for the treatment of colitis in a murine model using oral administration. Separately, Huang et al. [33] prepared nucleic acid-loaded nanoparticles targeted to colonic macrophages. When given orally, these nanoparticles can be loaded with therapeutic agents that could be applied clinically. However, their studies were unable to monitor the activity level or drug distribution of intestinal inflammation in vivo.

Nanoparticles can also possess multiple functions when used as theranostic agents. Theranostic agents are agents which combine diagnosis and treatment, such as the combination of a contrast agent with a drug. Several studies have reported this method and found success in imaging using an in vivo imaging system or MRI [34, 43].

Despite the advantages of nanomedicine-based treatments, the major side effects primarily derive from the drug loaded within the carrier. For instance, recent studies have shown that gadolinium may exhibit deposition in the brain [44]. While concerning, no neurological symptoms have been reported to date [45]. Yet, gadolinium is contraindicated in patients with renal dysfunction due to the increased risk of nephrogenic fibrosis [44]. Finally, oral administration or enema administration has been shown to decrease side effects compared with iv injection, indicating the important role of the route of administration.

In spite of the findings listed herein, some limitations to the current study still exist. Firstly, only a few cases were recruited in each zoopery. Secondly, all research studies conducted were with animal studies, and further exploration

Figure 3: The absorption pathway of SLN. Lymphatic circulation plays an important role in SLN absorption [25]. Typically, most SLNs are either taken up by the M-cells overlying the lymphoid follicles, Peyer’s patches, and circumambient lymphatic drainage, or transported via capillaries in direct or paracellular pathways [26–28]. However, in pathological situations, SLNs are primarily absorbed into the submucosal capillary network through the impaired colorectal mucosa. Furthermore, PEG-modified nanoparticles were more inclined to deposit at this lesion.
is required to highlight the advantages that molecular MRI can have on the diagnosis of IBD for clinical trials. Thirdly, the sensitivity of MRI molecular imaging (micromolar) in comparison with positron emission tomography (picomolar) has a gap [46]. Through advances in molecular biology, nanoparticle-based targeted carriers, and bioengineering, the sensitivity of MRI for molecular imaging has risen. Undoubtedly, MRI imaging has proven itself as a highly versatile modality for the molecular imaging of inflammatory bowel disease, particularly for nanoscience-based delivery approaches.

5. Conclusions

With the development of a nanoparticle-based MR contrast agent, molecular MR imaging of IBD may improve and allow for (1) a comprehensive visual image of complex biological processes, demonstrating a new way to understand the molecular mechanisms of IBD; (2) monitoring of multiple processes at the same time; (3) improvement of early detection of IBD or metaplasia; and (4) monitoring of the mechanistic of drug delivery and efficacy in vivo. Furthermore, the advent of theranostics has been paving the way for combined modalities incorporating both diagnostics and therapy. When used in conjunction with MRI, nanomedicine-based therapies can greatly improve the diagnosis and treatment of IBD. The absorption characteristics of the intestinal tract provide a convenient basis for the oral administration of nanoparticles, which both improves patient compliance and decreases the incidence of adverse effects.

Conflicts of Interest

The authors declare that there are no conflicts of interest regarding the publication of this paper.

Acknowledgments

The authors thank Professor Jihong Sun from Sir Run Run Shaw Hospital for useful discussions during the progression of the work. This work was supported by the National Natural Science Foundation of China (81971600) and Natural Science Foundation of Zhejiang Province of China (LSY19H030001 and LSY19H180003).

References


